Hormonal
Tirzepatide (a dual GLP-1RA/GIP agonist) produces superior mean weight loss (18.4%) compared to other FDA-approved pharmacotherapies for obesity, including semaglutide, phentermine-topiramate, and orlistat.
If you have obesity and lifestyle changes alone haven't worked, Tirzepatide is currently the most effective FDA-approved medication for weight loss, showing nearly 18% average weight loss in clinical trials. It requires weekly injections and careful dose titration to manage gastrointestinal side effects, but it offers superior results compared to older drugs like Orlistat or Phentermine-Topiramate.
Tirzepatide, a novel GLP-1RA and GIP agonist, recently completed a phase-3 RCT, which showed that over 72 weeks, the mean weight percentage decrease was 18.4% (95% CI: 18.5%-23.2%) vs a 3.1% weight gain with placebo, a change of 21.8%. ... Semaglutide is a well-established drug with weight loss, but tirzepatide shows the most promise in being the superior agent.
Why this rating
Based on a phase-3 RCT (SURMOUNT-3) and meta-analyses, though head-to-head trials with other GLP-1RAs are noted as needing further research.
Source
Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
Andrew Overholser et al. · Translation The University of Toledo Journal of Medical Sciences · 2025
DOI 10.46570/utjms-2024-1218
More from this paper
- Semaglutide (a GLP-1RA) produces significant weight loss (10-12.5%) and improves cardiometabolic risk factors, making it more effective than older pharmacotherapies like Phentermine-Topiramate and Orlistat.Good
- Phentermine-Topiramate produces moderate weight loss (7.87-8.45%) and improves cardiometabolic risk factors, but carries higher risks of neuropsychiatric and cardiovascular side effects compared to GLP-1RAs.Good
- Orlistat produces minimal weight loss (2.78-3.16%) and has a high gastrointestinal side effect profile, making it a less effective first-line treatment compared to GLP-1RAs.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →